Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 12/20 | 0.60 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL65681 | 0.88 | TDP1 (0.54) | FFAR1KDM4EALDH1A1GAAPPARG | |
| SCHEMBL1206748 | 0.87 | LMNA (0.68) | FFAR1PPARDFFAR4PPARGPPARA | |
| SCHEMBL1206101 | 0.85 | PPARA (0.64) | FFAR1PPARGPPARALMNAL3MBTL1 | |
| SCHEMBL6063728 | 0.85 | FFAR1 (0.58) | FFAR1PPARDFFAR4PPARA | |
| SCHEMBL18301907 | 0.85 | PLA2G4B (0.59) | FFAR1PPARDKDM4EALDH1A1GAA | |
| SCHEMBL17413767 | 0.85 | FFAR1 (0.71) | FFAR1PPARDFFAR4 | |
| SCHEMBL2741520 | 0.84 | LMNA (0.54) | FFAR1FFAR4KDM4EALDH1A1LMNA | |
| SCHEMBL17413763 | 0.84 | FFAR1 (0.69) | FFAR1PPARDFFAR4PPARGPPARA | |
| SCHEMBL1205963 | 0.83 | FFAR1 (0.61) | FFAR1PPARDFFAR4PPARGPPARA | |
| SCHEMBL25456542 | 0.83 | PPARA (0.69) | FFAR1PPARGPPARACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812038-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | BIEDIGER RONALD J | 2006-12-07 | — | — | US | disclosed |
| US-6972296-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, ITGA1 | FFAR1 74/4885PPARD 609/4885FFAR4 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.